This paper is in the following e-collection/theme issue:

Non-Randomized Studies (funded, non-eHealth) (135)

Published on in Vol 8, No 4 (2019): April

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/12125, first published .
Safety of Intranasal Ketamine for Reducing Uncontrolled Cancer-Related Pain: Protocol of a Phase I/II Clinical Trial

Safety of Intranasal Ketamine for Reducing Uncontrolled Cancer-Related Pain: Protocol of a Phase I/II Clinical Trial

Safety of Intranasal Ketamine for Reducing Uncontrolled Cancer-Related Pain: Protocol of a Phase I/II Clinical Trial

Authors of this article:

Jack W Shteamer1 Author Orcid Image ;   R Donald Harvey2, 3 Author Orcid Image ;   Boris Spektor1 Author Orcid Image ;   Kimberly Curseen4 Author Orcid Image ;   Katherine Egan1 Author Orcid Image ;   Zhengjia Chen5, 6 Author Orcid Image ;   Theresa W Gillespie7 Author Orcid Image ;   Roman M Sniecinski1 Author Orcid Image ;   Vinita Singh1 Author Orcid Image
Article Authors Cited by (2) Tweetations (2) Metrics

Journals

  1. Fernandes M, Schelotto M, Doldi P, Milani G, Ariza Manzano A, Perera Valdivia D, Winter Matos A, Hamdy Abdelrahim Y, Hamad Bek S, Benitez B, Romanelli Tavares V, Basendwah A, Albuquerque Sousa L, Xavier N, Zertuche Maldonado T, Toyomi de Oliveira S, Chaker M, Menon Miyake M, Uygur Kucukseymen E, Waqar K, Alkhozondar O, Bernardo da Silva R, Droppelmann G, Vaz de Macedo A, Nakamura R, Fregni F. IMPORTANCE trial: a provisional study-design of a single-center, phase II, double-blinded, placebo-controlled, randomized, 4-week study to compare the efficacy and safety of intranasal esketamine in chronic opioid refractory pain. F1000Research 2021;10:42 View
  2. Chung M, Benkli B, Roldan C, Qing Y, Wang J, Huh B. Subanesthetic Ketamine in the Ambulatory Setting for Refractory Cancer Pain: A 6-Year Retrospective at a Cancer Center. Pain Management 2021;11(3):267 View